Good latest quarter from BMS

Bristol-Myers Squibb today has published, before trading opened in Wall Street, its fourth-quarter 2018 results. The data show a robust growth, which in the latest quarter has yielded a sales of $6bn (+10% vs Q4 2017) with a net profit of $1.2bn.

Immunotherapy Opdivo (+33%) and anticoagulant Eliquis confirm themselves as the US-based group’s top selling drugs.  Today BMS has also announced it has withdrawn its application for the Opdivo-Yervoy combo therapy, which has probably caused shares to drop (-3%) in pre-market trading.

(Source: WSJ)